Lung cancer trials in China

In China 1142 Also abroad 2735

1,142 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)
Where
Anyang, Baoding, Beijing, Cangzhou, Changzhi, Chengdu, Fuzhou, Guangzhou, Handan, Hefei, Huzhou, Jinan, Jining, Linhai, Linyi, Lishui, Liuzhou, Nanchang, Nanjing, Nanning, Nantong, Qiqihar, Shanghai, Shaoxing, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Suining, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Wuhan, Wuhu, Xiamen, Xi'an, Xiangyang, Yangzhou, Zhoushan, Zunyi
Age
18 years and over
People
1,000
Run by
AstraZeneca
See details and how to joinNCT07613424
No phaseTaking people
Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.
Where
Shanghai
Age
18 years to 90 years
People
294
Run by
Shanghai Chest Hospital
See details and how to joinNCT07681245
No phaseTaking people
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Where
Beijing
Age
18 years to 85 years
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07894458
No phaseTaking people
Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules
Where
Wuhan
Age
35 years and over
People
6,000
Run by
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07895277
Phase 3Not yet taking people in China
SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study
Where
Guangzhou
Age
18 years to 75 years
People
490
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07895992
Phase 3Not yet taking people in China
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
Where
Hangzhou, Shanghai
Age
18 years to 75 years
People
436
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07896005
No phaseTaking people
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Where
Beijing
Age
18 years to 80 years
People
470
Run by
Sun Yat-sen University
See details and how to joinNCT06644430
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Hong Kong, Jinan, Jordan, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 2/3Taking people
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
590 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00
Phase 1/2Taking people
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Shengyang, Taizhou, Tianjin
Age
18 years and over
People
220
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07079475
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shanghai Shi, Shantou, Shenyang, Wuhan, Xiamen, Xi'an, Xiangyang, Zhangzhou, Zhengzhou
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
61
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07416058
Phase 2Taking people
Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)
Where
Guangzhou
Age
18 years to 80 years
People
32
Run by
Guangdong Provincial People's Hospital
See details and how to joinNCT07472478
Phase 2Taking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Beijing, Chengdu, Fuzhou, Hangzhou, Nanjing, Shanghai, Wuhan
Age
18 years and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
Phase 2Taking people
A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Where
Wuhan
Age
18 years and over
People
76
Run by
Hansoh BioMedical R&D Company
See details and how to joinNCT07824882
Phase 2Taking people
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Where
Beijing, Fuzhou, Harbin, Linyi, Nanchang, Nanning, Ürümqi, Wuhan, Xi'an, Zhengzhou
Age
18 years and over
People
150 worldwide
Run by
AbbVie
See details and how to joinNCT06568939
Phase 1/2Taking people
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Where
Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
Age
18 years and over
People
880 worldwide
Run by
BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00
No phaseNot yet taking people in China
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
Where
Shanghai
Age
18 years and over
People
15
Run by
Shanghai Chest Hospital
See details and how to joinNCT07889297
Phase 2Not yet taking people in China
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Where
Shanghai
Age
18 years to 75 years
People
64
Run by
Ruijin Hospital
See details and how to joinNCT07890636
Phase 2Taking people
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Where
Beijing, Changchun, Guangzhou, Xi’an
Age
18 years and over
People
320 worldwide
Run by
Pfizer
See details and how to joinNCT04606446
Phase 1/2Taking people
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Where
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taizhou, Tianjin, Wuhan, Xi’an, Xinxiang, Zhengzhou
Age
18 years and over
People
862 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT05914116
No phaseTaking people
A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China
Where
Beijing
Age
18 years and over
People
3,000
Run by
AstraZeneca
See details and how to joinNCT07316062
No phaseTaking people
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
Where
Guangzhou
Age
18 years and over
People
265
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT07696832
Phase 2Not yet taking people in China
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
Where
Beijing
Age
18 years and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07885709
Phase 1Taking people
Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer
Where
Changsha
Age
18 years to 75 years
People
18
Run by
Second Xiangya Hospital of Central South University
See details and how to joinNCT07886047